Clinical trial
Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not…
NCT00114699 · Human Genome Sciences Inc., Industry · Completed
Key facts
| NCT number | NCT00114699 |
|---|---|
| Title | Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy |
| Official title | A Phase 1, Randomized, Placebo-Controlled, Single-Injection, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ccr5mab004 (Human Monoclonal Igg4 Antibody To Ccr5) in Hiv-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral… |
| Lead sponsor | Human Genome Sciences Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | CCR5mAb004 |
| Enrollment | 40 |
| Start date | Apr 1, 2005 |
| Completion | Apr 1, 2006 |
| First posted | Jun 17, 2005 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: